vitamin K-dependent clotting factors, combined deficiency of, type 2

disease
On this page

Also known as congenital vitamin K-dependent coagulation factors combined deficiency caused by mutation in VKORC1vitamin K-dependent clotting factors, combined deficiency of, 2VKCFD2VKORC1 congenital vitamin K-dependent coagulation factors combined deficiency

Summary

vitamin K-dependent clotting factors, combined deficiency of, type 2 (MONDO:0011837) is a disease caused by VKORC1 (GenCC Strong), with 1 cohort gene.

At a glance

  • Causal gene: VKORC1 (GenCC Strong)
  • Cohort genes: 1
  • ClinVar variants: 24

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namevitamin K-dependent clotting factors, combined deficiency of, type 2
Mondo IDMONDO:0011837
MeSHC564393
OMIM607473
DOIDDOID:0112174
UMLSC1843832
MedGen334505
GARD0018196
Is cancer (heuristic)no

Also known as: congenital vitamin K-dependent coagulation factors combined deficiency caused by mutation in VKORC1 · vitamin K-dependent clotting factors, combined deficiency of, 2 · vitamin K-dependent clotting factors, combined deficiency of, type 2 · VKCFD2 · VKORC1 congenital vitamin K-dependent coagulation factors combined deficiency

Data availability: 24 ClinVar variants · 2 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by body system or component › hematologic disorderblood coagulation diseasecoagulation protein diseasecongenital vitamin K-dependent coagulation factors deficiencyvitamin K-dependent clotting factors, combined deficiency of, type 2

Related subtypes (4): congenital factor VII deficiency, congenital factor X deficiency, vitamin K-dependent clotting factors, combined deficiency of, type 1, congenital prothrombin deficiency

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

24 retrieved; paginated sample, class counts are floors:

14 uncertain significance, 3 benign, 2 drug response, 2 likely benign, 1 likely pathogenic, 1 conflicting classifications of pathogenicity, 1 benign/likely benign

ClinVarVariant (HGVS)GeneClassificationReview
2206NM_024006.6(VKORC1):c.292C>T (p.Arg98Trp)VKORC1Likely pathogeniccriteria provided, single submitter
2212NM_024006.6(VKORC1):c.106G>T (p.Asp36Tyr)VKORC1drug responsereviewed by expert panel
226016NM_024006.6(VKORC1):c.*134G>AVKORC1drug responsereviewed by expert panel
692018NM_024006.6(VKORC1):c.196G>A (p.Val66Met)VKORC1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
318973NM_024006.6(VKORC1):c.*245G>AVKORC1Uncertain significancecriteria provided, single submitter
318976NM_024006.6(VKORC1):c.267A>T (p.Thr89=)VKORC1Uncertain significancecriteria provided, single submitter
4277943NM_024006.6(VKORC1):c.230A>G (p.Asn77Ser)VKORC1Uncertain significancecriteria provided, single submitter
884452NM_024006.6(VKORC1):c.117C>T (p.Tyr39=)VKORC1Uncertain significancecriteria provided, multiple submitters, no conflicts
884453NM_024006.6(VKORC1):c.54G>T (p.Thr18=)VKORC1Uncertain significancecriteria provided, single submitter
884454NM_024006.6(VKORC1):c.-2T>CVKORC1Uncertain significancecriteria provided, single submitter
884455NM_024006.6(VKORC1):c.-45G>AVKORC1Uncertain significancecriteria provided, single submitter
887421NM_024006.6(VKORC1):c.*172T>AVKORC1Uncertain significancecriteria provided, single submitter
887422NM_024006.6(VKORC1):c.*10C>GVKORC1Uncertain significancecriteria provided, single submitter
887423NM_024006.6(VKORC1):c.447T>C (p.Ser149=)VKORC1Uncertain significancecriteria provided, single submitter
887424NM_024006.6(VKORC1):c.379G>A (p.Val127Met)VKORC1Uncertain significancecriteria provided, single submitter
887599NM_024006.6(VKORC1):c.342C>G (p.Leu114=)VKORC1Uncertain significancecriteria provided, single submitter
887601NM_024006.6(VKORC1):c.202C>T (p.His68Tyr)VKORC1Uncertain significancecriteria provided, single submitter
887602NM_024006.6(VKORC1):c.173+11G>TVKORC1Uncertain significancecriteria provided, single submitter
318975NM_024006.6(VKORC1):c.358C>T (p.Leu120=)VKORC1Benigncriteria provided, multiple submitters, no conflicts
318977NM_024006.6(VKORC1):c.36G>A (p.Arg12=)VKORC1Benigncriteria provided, multiple submitters, no conflicts
791061NM_024006.6(VKORC1):c.129C>T (p.Cys43=)VKORC1Benign/Likely benigncriteria provided, multiple submitters, no conflicts
887420NM_024006.6(VKORC1):c.*243G>AVKORC1Likely benigncriteria provided, single submitter
887598NM_024006.6(VKORC1):c.352G>C (p.Val118Leu)VKORC1Likely benigncriteria provided, single submitter
887600NM_024006.6(VKORC1):c.203A>G (p.His68Arg)VKORC1Benigncriteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 4 · Orphanet: 1 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
VKORC1StrongAutosomal recessivevitamin K-dependent clotting factors, combined deficiency of, type 24

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
VKORC1Orphanet:98434Hereditary combined deficiency of vitamin K-dependent clotting factors

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
VKORC1HGNC:23663ENSG00000167397Q9BQB6Vitamin K epoxide reductase complex subunit 1gencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
VKORC1Vitamin K epoxide reductase complex subunit 1Involved in vitamin K metabolism.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Enzyme (other)112.0×0.083

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
VKORC1Enzyme (other)yes1.17.4.4VKOR, VKOR_sf, VKORC1/VKORC1L1

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
right lobe of liver1
stromal cell of endometrium1
thoracic aorta1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
VKORC1134ubiquitousmarkerstromal cell of endometrium, right lobe of liver, thoracic aorta

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
VKORC11,009

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
VKORC1Q9BQB66

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 1. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Metabolism of vitamin K13806.7×3e-04VKORC1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
peptidyl-glutamic acid carboxylation18426.0×7e-04VKORC1
positive regulation of coagulation12808.7×9e-04VKORC1
vitamin K metabolic process12106.5×9e-04VKORC1
bone development1276.3×0.005VKORC1
blood coagulation1173.7×0.007VKORC1
xenobiotic metabolic process1149.1×0.007VKORC1

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

SymbolExample approved molecule
VKORC1WARFARIN

Top cohort targets by molecule count

SymbolMoleculesMax phase
VKORC114

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
WARFARIN4VKORC1

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
VKORC13Binding:3

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
VKORC11.17.4.4vitamin-K-epoxide reductase (warfarin-sensitive)

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 1.

Cohort genes with a CPIC/DPWG dosing guideline

SymbolCPIC guidelines
VKORC11

Chemical tractability of cohort targets

1 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

CompoundMax phaseCohort target (bioactivity)
WARFARIN4VKORC1

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)1VKORC1
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 0.